Bio-Rad Laboratories, Inc.
General ticker "BIO-B" information:
- Sector: Health Care
- Industry: Medical - Devices
- Capitalization: $7.7B (TTM average)
Bio-Rad Laboratories, Inc. follows the US Stock Market performance with the rate: 30.6%.
Estimated limits based on current volatility of 1.8%: low 258.01$, high 267.64$
Factors to consider:
- Total employees count: 7700 as of 2024
- US accounted for 40.6% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Geopolitical risks, Regulatory and compliance, Cybersecurity threats, Organizational changes, Climate change and natural disasters
- Price in estimated range
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [232.11$, 351.16$]
- 2026-12-31 to 2027-12-31 estimated range: [227.13$, 347.53$]
Financial Metrics affecting the BIO-B estimates:
- Negative: with PPE of 82.4 at the end of fiscal year the price was high
- Positive: -4.95 < Operating profit margin, % of 1.83
- Positive: Return on assets ratio (scaled to [-100,100]) of 6.70 > 6.07
- Positive: Shareholder equity ratio, % of 70.47 > 64.15
- Positive: Industry inventory ratio change (median), % of -0.27 <= -0.16
- Positive: 0.02 < Operating cash flow per share per price, % of 6.28
- Positive: Interest expense per share per price, % of 0.58 <= 0.73
Short-term BIO-B quotes
Long-term BIO-B plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $2,671.20MM | $2,566.50MM | $2,583.20MM |
| Operating Expenses | $2,333.40MM | $2,297.50MM | $2,536.00MM |
| Operating Income | $337.80MM | $269.00MM | $47.20MM |
| Non-Operating Income | $-1,187.90MM | $-2,611.50MM | $948.30MM |
| Interest Expense | $49.40MM | $48.90MM | $49.00MM |
| R&D Expense | $247.40MM | $295.90MM | $275.60MM |
| Income(Loss) | $-850.10MM | $-2,342.50MM | $995.50MM |
| Taxes | $-212.80MM | $-498.30MM | $235.60MM |
| Profit(Loss)* | $-637.32MM | $-1,844.20MM | $759.90MM |
| Stockholders Equity | $8,741.20MM | $6,569.30MM | $7,453.60MM |
| Inventory | $780.50MM | $760.00MM | $740.70MM |
| Assets | $12,299.10MM | $9,364.10MM | $10,576.50MM |
| Operating Cash Flow | $374.94MM | $455.20MM | $532.20MM |
| Capital expenditure | $156.68MM | $189.00MM | $157.60MM |
| Investing Cash Flow | $20.21MM | $-160.20MM | $-189.70MM |
| Financing Cash Flow | $-425.65MM | $-218.80MM | $-283.20MM |
| Earnings Per Share** | $-21.82 | $-65.36 | $27.87 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.